These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36701644)

  • 1. Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial.
    Sura AA; Sun Y; Reddy AK; Rathinam SR; Gonzales JA; Thundikandy R; Vedhanayaki R; Kanakath A; Murugan B; Doan TA; Lim LL; Suhler EB; Al-Dhibi HA; Acharya NR;
    Ocul Immunol Inflamm; 2024 Aug; 32(6):955-960. PubMed ID: 36701644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.
    Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Keenan JD; Rao MM; Ebert CD; Nguyen HH; Kim E; Porco TC; Acharya NR;
    JAMA; 2019 Sep; 322(10):936-945. PubMed ID: 31503307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.
    Kong CL; Kelly NK; Sundararajan M; Rathinam SR; Gonzales JA; Thundikandy R; Vedhanayaki R; Kanakath A; Murugan B; Doan T; Goldstein D; Al-Dhibi HA; Acharya NR
    Ocul Immunol Inflamm; 2022 Jan; 30(1):198-202. PubMed ID: 32779952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.
    Tsui E; Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Balamurugan S; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Keenan J; Ebert CD; Kim E; Madow B; Porco TC; Acharya NR;
    Ophthalmology; 2022 Jun; 129(6):661-667. PubMed ID: 35143800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis.
    Rathinam SR; Babu M; Thundikandy R; Kanakath A; Nardone N; Esterberg E; Lee SM; Enanoria WT; Porco TC; Browne EN; Weinrib R; Acharya NR
    Ophthalmology; 2014 Oct; 121(10):1863-70. PubMed ID: 24917273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis.
    Sobrin L; Christen W; Foster CS
    Ophthalmology; 2008 Aug; 115(8):1416-21, 1421.e1. PubMed ID: 18221998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases.
    Gangaputra SS; Newcomb CW; Joffe MM; Dreger K; Begum H; Artornsombudh P; Pujari SS; Daniel E; Sen HN; Suhler EB; Thorne JE; Bhatt NP; Foster CS; Jabs DA; Nussenblatt RB; Rosenbaum JT; Levy-Clarke GA; Kempen JH;
    Am J Ophthalmol; 2019 Dec; 208():68-75. PubMed ID: 31344346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.
    Galor A; Jabs DA; Leder HA; Kedhar SR; Dunn JP; Peters GB; Thorne JE
    Ophthalmology; 2008 Oct; 115(10):1826-32. PubMed ID: 18579209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.
    Shen E; Rathinam SR; Babu M; Kanakath A; Thundikandy R; Lee SM; Browne EN; Porco TC; Acharya NR
    Am J Ophthalmol; 2016 Aug; 168():279-286. PubMed ID: 27296490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis.
    Kelly NK; Chattopadhyay A; Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Cugley D; Lim LL; Suhler EB; Al-Dhibi HA; Ebert CD; Berlinberg EJ; Porco TC; Acharya NR;
    Ophthalmology; 2021 Sep; 128(9):1337-1345. PubMed ID: 33675850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian Analysis of a Randomized Clinical Trial Comparing Antimetabolite Therapies for Non-Infectious Uveitis.
    Browne EN; Rathinam SR; Kanakath A; Thundikandy R; Babu M; Lietman TM; Acharya NR
    Ophthalmic Epidemiol; 2017 Feb; 24(1):63-70. PubMed ID: 27982726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil as an immunomodulator in refractory noninfectious uveitis.
    Rodriguez EE; Sakata VM; Cavalcanti DC; Zaghetto JM; Olivalves E; Hirata CE; Yamamoto JH
    Arq Bras Oftalmol; 2016; 79(6):369-372. PubMed ID: 28076562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial.
    Reddy AK; Miller DC; Sura AA; Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan B; Vedhanayaki R; Lim LL; Suhler EB; Doan T; Al-Dhibi HA; Goldstein DA; Arellanes-Garcia L; Acharya NR
    J Ophthalmic Inflamm Infect; 2023 Jun; 13(1):29. PubMed ID: 37294447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil in the treatment of uveitis in children.
    Doycheva D; Deuter C; Stuebiger N; Biester S; Zierhut M
    Br J Ophthalmol; 2007 Feb; 91(2):180-4. PubMed ID: 16825275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis.
    Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Deuter C
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1235-43. PubMed ID: 21720813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.
    Acharya NR; Rathinam SR; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Gonzales JA; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Arellanes-Garcia L; Coyne A; Porco TC; Shantha JG;
    Am J Ophthalmol; 2024 Jun; 267():100-111. PubMed ID: 38909740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis].
    Zierhut M; Stübiger N; Aboalchamat W; Landenberger H; Bialasiewicz AA; Engelmann K
    Ophthalmologe; 2001 Jul; 98(7):647-51. PubMed ID: 11490743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation.
    Lau CH; Comer M; Lightman S
    Clin Exp Ophthalmol; 2003 Dec; 31(6):487-91. PubMed ID: 14641155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
    Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.